Defect AI (Rette)

Almaty / Palo Alto
HealthTech & MedTech Pre-seed Open sources

AI auditing of medical documentation and insurance claims. Team based in Kazakhstan, Rette HQ in the US; participant in Stanford StartX and Mayo Clinic Accelerate.

About

Defect AI (operating in the US as Rette Inc.; its corporate LinkedIn profile lists 2025 as the founding year, while the launch date of Defect AI in Kazakhstan is being clarified) is a medical artificial intelligence platform for auditing clinical documentation and reducing financial claim denials by insurance funds. The founders are Sanzhar Myrzagalym, Kuanysh Idrissov, and Zharaskhan Aman. The technical team is based in Kazakhstan, while Rette Inc. is headquartered in Palo Alto (USA). According to a Digital Business article dated 09.09.2026, the system has been tested in approximately 30 clinics in Kazakhstan and is piloting orthopedic documentation in the US (the project completed Stanford StartX and was selected for Mayo Clinic Platform_Accelerate). In late 2025, the startup raised its first investment round from 500 Eurasia, JAS Ventures, and Astana Hub Ventures (check size undisclosed), and as of the September 2026 interview had opened a US pre-seed round to convert its American pilots into commercial contracts.

More about the founder: Sanzhar Myrzagalym: Co-founder of Rette and Defect AI — from Microsoft to Medical AI.

Founders

SM
Sanzhar Myrzagalym
KI
Kuanysh Idrissov
ZA
Zharaskhan Aman

Team information is compiled from open sources and may be updated by our editors.

RAEM Coverage

Profile history

Profile published in directory
Editorial data verification

Sources

Is this your company?

Verify that you represent Defect AI (Rette) to update this profile and receive inquiries from investors and partners.

Similar startups

All in sector →
Defect AI (Rette)HealthTech · Almaty / Palo AltoWebsite ↗
REPRESENTATIVE VERIFICATION

Claim company representative access

Verified representatives can update metrics, publish company news to the feed, and receive direct investor inquiries.

✓

Request sent